Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptors and adaptors thereof
US-2018201663-A1 · Jul 19, 2018 · US
Induced activation in dendritic cells
US10420824B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10420824-B2 |
| Application number | US-201715399512-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 5, 2017 |
| Priority date | Feb 18, 2003 |
| Publication date | Sep 24, 2019 |
| Grant date | Sep 24, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
First claim
Opening claim text (preview).
What is claimed is: 1. An ex vivo nucleic acid comprising a polynucleotide promoter sequence operatively linked to a polynucleotide sequence encoding a chimeric protein comprising (a) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain, and (b) a ligand binding region comprising a FKBP12(V36) polypeptide. 2. The nucleic acid of claim 1 , wherein the nucleic acid is isolated. 3. The nucleic acid of claim 1 , wherein the ligand binding region comprises two or more FKBP12(V36) polypeptides. 4. The nucleic acid of claim 3 , wherein the ligand binding region is amino terminal to the CD40 cytoplasmic polypeptide region of the chimeric protein. 5. The nucleic acid of claim 1 , wherein the nucleic acid is contained within a vector. 6. The nucleic acid of claim 5 , wherein the nucleic acid is contained within a viral vector. 7. The nucleic acid of claim 5 , wherein the nucleic acid is contained within a plasmid vector. 8. An ex vivo antigen-presenting cell transduced or transfected with the nucleic acid of claim 5 . 9. An ex vivo nucleic acid comprising a polynucleotide promoter sequence operatively linked to a polynucleotide sequence encoding a chimeric protein comprising (a) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain, and (b) an FK506 ligand binding polypeptide region that binds to AP1903 or AP20187. 10. The nucleic acid of claim 9 , wherein the FK506 ligand binding region comprises two or more FK506 ligand binding polypeptides. 11. The nucleic acid of claim 9 , wherein the nucleic acid is isolated. 12. The nucleic acid of claim 9 , wherein the ligand binding polypeptide region is amino terminal to the CD40 cytoplasmic polypeptide region of the chimeric protein. 13. The nucleic acid of claim 9 , wherein the nucleic acid is contained within a vector. 14. The nucleic acid of claim 13 , wherein the nucleic acid is contained within a viral vector. 15. The nucleic acid of claim 13 , wherein the nucleic acid is contained within a plasmid vector. 16. An ex vivo antigen-presenting cell transduced or transfected with the nucleic acid of claim 13 .
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Glutamate carboxypeptidase II (3.4.17.21) · CPC title
Receptors; Cell surface antigens; Cell surface determinants · CPC title
Viral antigens · CPC title
Animal cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10420824B2 cover?
- The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
- Who is the assignee on this patent?
- Baylor College Medicine
- What technology area does this patent fall under?
- Primary CPC classification A61K39/02. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).